1 Next, we tested FHOD3-V1151I (rs2303510), a nonsynonymous var
2 Next, we tested for evidence of assembly processes that might
3 Next, we tested for evidence of reentry and DNA synthesis in
4 Next, we tested for generalizability of our technique by appl
5 Next, we tested in the pxa1/pxa2Delta yeast mutant the functi
6 Next, we tested MDR activity in two paired AML patient sample
7 Next, we tested six melanoma-derived cell lines for evidence
8 Next, we tested the ability of peptides encompassing the enti
9 Next, we tested the cathelin-like protein for antimicrobial a
10 Next, we tested the effect of rAAV-mediated expression of IFN
11 Next, we tested the enzymatic activity of a recombinant mutan
12 Next, we tested the evolutionary specificity of this interact
13 Next, we tested the hypothesis that baclofen modulates LES mo
14 Next, we tested the impact of the signal transduction inhibit
15 Next, we tested the possible therapeutic application of the F
16 Next, we tested the role of miR-21 in regulating TGF-beta sig
17 Next, we tested the sensitivity and specificity of the derive
18 Next, we tested the therapeutic efficacy of bone morphogenic
19 Next, we tested two mutated versions of NCS-1 developed with
20 Next, we tested whether disparate activity patterns during di
21 Next, we tested whether in vivo exposure of rats to alcohol l
22 Next, we tested whether oncogenic PIK3CA, like inactivated PT
23 Next, we tested whether the decision boundary generated from
24 Next, we tested whether the LCR is necessary to activate glob
25 Next, we tested whether the synaptic protein response to HDAC
26 Next, we tested whether uric acid might mediate inflammasome